Empowering Innovation: ProtaGene’s Analytical Solutions Amid Market Flux

The biopharmaceutical industry is continuing to find its footing after the tumultuous pandemic years. During the pandemic, we saw a significant increase in outsourcing analytical testing and product characterization services to meet urgent demands and restrictions on lab operating procedures due to social distancing requirements.

However, as we observe today’s market, we’re seeing increased analytical services outsourcing for different reasons— increased demand for efficiency of budget usage in the current market.

• In 2022, the collective revenues of public biotech companies in the US and Europe were down ~1% compared to 2021.
• 2023 drug approvals are returning to pre-pandemic levels; however, they were down again in 2022 due to regulatory body staffing shortages and backlog due to wide-scale pandemic disruptions.
• The biotech investment market is strained. Investment in earlier-phase start-ups is predicted to be 40% below 2022.

Drug developers face a complex and difficult-to-predict journey, so they must prioritize their resources to meet pipeline and commercialization objectives while acknowledging resource constraints. To avoid over- or under-resourcing their analytical departments, innovator teams are turning to ProtaGene. We are a collaborative analytical partner that can seamlessly integrate with our clients’ in-house analytical teams, allowing rapid scale-up or scale-down of analytical resources.